Durect corporation to announce first quarter 2024 financial results and provide a business update

Cupertino, calif. , may 7, 2024 /prnewswire/ -- durect corporation (nasdaq: drrx), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its first quarter financial results on monday, may 13, 2024.
DRRX Ratings Summary
DRRX Quant Ranking